315 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Kelly
    Kelly
  4. Gerecitano
    Gerecitano
  5. O'Reilly
    O'Reilly
  6. Slovin
    Slovin
  7. Smart-Curley
    Smart-Curley
  8. Morris
    Morris
  9. Schwartz
    Schwartz
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)
  7. Biostatistics Service (45)
  8. Survivorship Research (45)
  9. Radiology, Department of (42)
  10. Nursing (41)
  1. "hyperglycemia"
Formats
  1. Journal Article (294)
  2. Review (17)
  3. Guidelines (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)

More Groups

People
  1. Robert Motzer (28)
  2. Howard Scher (15)
  3. William Kelly (14)
  4. Eileen O'Reilly (11)
  5. John Gerecitano (11)
  6. Susan Slovin (11)

More People

Years
  1. 2025 (8)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (9)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (20)
  3. Cancer (14)
  4. Lancet Oncology (14)
  5. Annals of Oncology (12)
  6. Investigational New Drugs (12)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (32)
  3. American Society of Clinical Oncology (28)
  4. Elsevier Science, Inc. (23)
  5. Oxford University Press (23)
  6. American Association for Cancer Research (21)

More Publishers

Results (315)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in patients with advanced NSCLC (NCI 10327): Rationale and study design
    Journal Article

    Riess, J. W.; Frankel, P.; Shackelford, D.; Dunphy, M.; Badawi, R. D.; Nardo, L.; Cherry, S. R.; Lanza, I.; Reid, J.; Gonsalves, W. I.; more...
    Clinical Lung Cancer (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Phase II evaluation of copanlisib, a selective inhibitor of PI3KCA, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
    Journal Article

    Santin, A. D.; Filiaci, V.; Bellone, S.; O'Cearbhaill, R.; Ratner, E. S.; Mathews, C. A.; Cantuaria, G.; Gunderson, C. C.; Rutledge, T.; Buttin, B. M.; more...
    Gynecologic Oncology Reports (2020)

    Fulltext@MSK | Save
  • Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
    Review

    Cooksley, T.; Girotra, M.; Ginex, P.; Gordon, R. A.; Anderson, R.; Blidner, A.; Choi, J.; Dougan, M.; Glezerman, I.; Gupta, D.; more...
    Supportive Care in Cancer (2020)

    Fulltext@MSK | Save
  • A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma
    Journal Article

    El Dika, I.; Mayer, R. J.; Venook, A. P.; Capanu, M.; LaQuaglia, M. P.; Kobos, R.; O'Neill, A. F.; Chou, J. F.; Ly, M.; Ang, C.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Journal Article

    Landgren, C. O.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J. A.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; more...
    Leukemia (2020)

    Fulltext@MSK | Save
  • The emerging role of antibody-drug conjugates in urothelial carcinoma
    Review

    Lattanzi, M.; Rosenberg, J. E.
    Expert Review of Anticancer Therapy (2020)

    Fulltext@MSK | Save
  • DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
    Journal Article

    Wudhikarn, K.; Pennisi, M.; Garcia-Recio, M.; Flynn, J. R.; Afuye, A.; Silverberg, M. L.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; Shah, G. L.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners
    Guidelines

    Reed, M.; Rosales, A. L. S.; Chioda, M. D.; Parker, L.; Devgan, G.; Kettle, J.
    Advances in Therapy (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save